MedPath

Loyal's Loy-002 Shows Promise in Extending Dog Lifespan in Phase 2 Trial

• Loyal is conducting a Phase 2 clinical trial of Loy-002, a drug aimed at extending both the length and quality of life for aging dogs. • Early results from the trial indicate improved metabolic health in dogs, including better insulin sensitivity and muscle regulation. • Some participants have shown increased energy levels and physical activity, suggesting a potential reversal of aging effects. • The trial is ongoing, with hopes of future FDA approval to make the drug available for broader use in canines.

Springfield, MO – Loyal, a company focused on extending the healthy lifespan of dogs, is currently in Phase 2 clinical trials with its drug, Loy-002. The study aims to improve the metabolic health of aging dogs, potentially extending their lives and enhancing their quality of life. Early results are promising, with some participants showing signs of improved vitality.

Metabolic Improvements Observed

According to Dr. Alison Barulich, a veterinarian involved in the trial, Loy-002 targets the metabolic decline that typically occurs as dogs age. "As dogs age, like people, metabolic health declines. Things like insulin sensitivity, blood sugar regulation, muscling, body fat and where your body fat is becomes disregulated. The goal with this drug is improving regulation of metabolic health to help these guys live longer," she explained.
One participant, Robin Jackson, whose 11-year-old dog Reilly is enrolled in the trial, reported significant improvements in Reilly's activity levels. "We call him Benjamin Button. He’s aging backwards now," Jackson noted. She observed that Reilly, who has been taking a daily pill for six months, now moves more freely and engages in activities he hadn't done in a long time.

Blinded Study Design

The Phase 2 trial is a double-blinded study, meaning neither the pet owners nor the veterinarians know whether the dogs are receiving Loy-002 or a placebo. However, Dr. Barulich has observed changes in some dogs that suggest they are receiving the active drug. "I’ve seen things like blood lipids improve that I don’t have another explanation for," she stated.

Hope for Future Approval

While it may take several years before potential FDA approval, the early results have generated excitement among pet owners and veterinarians. Jackson is already looking forward to the possibility of using the drug to help her younger dogs as they age. "This is how we get this drug approved so that more dogs can benefit from it. I look at our little dog, our three year old dog and I want this ready for him when he can take it," she said.
The study is still enrolling dogs. Interested pet owners can visit Loyal’s website for more information.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Reference News

[1]
Leigh's Lost and Found: Local vet office takes part in clinical trial to extend dogs' lives - KY3
ky3.com · Sep 16, 2024

Loyal's phase two trial of Loy-002 aims to extend dogs' lives; Robin Jackson's 11-year-old dog Reilly shows significant ...

© Copyright 2025. All Rights Reserved by MedPath